投资建议：公司作为国内人二倍体疫苗企业，控股权变更带来的治理优化与资源协同预期叠加基本面修 复，将成为中长期配置的核心切入点。 万可欣生物（上海国资背景）于2025年11月7日正式入主，通过受让21.91%股份（受让价65.03元/股） 及表决权委托实现平稳控股权交接，交易额18.51亿元，公司承诺2025-2026年研发投入不低于2.6亿元以 加速管线推进；2025年三季报显示业绩降幅收窄（Q1/Q2/Q3营收同比-55.70%/-19.49%/+11.54%），Q1- 3归母净利润1.89亿元（Q1/Q2/Q3归母净利润同比-86.14%/-40.28%/-24.92%）；叠加原实控人业绩承诺 （2025-2026扣非净利合计不低于7.28亿元）提供缓冲；建议积极布局中长期成长机会，把握股权变更 与业绩复苏的认知差修复窗口。我们预计2025-2027年公司营收分别为12.99/15.30/16.58亿元，同比增 长-9.25%/17.76%/8.33%；归母净利润分别为3.01/5.01/6.38亿元，同比增长-24.60%/66.77%/27.26%，对 应PE分别为34/21/16倍，首次覆盖，给予" ...

Investment Rating - The industry investment rating is maintained at "Overweight" [4][11][28] Core Insights - The vaccine industry is currently transitioning from scale expansion to innovation-driven growth, facing short-term pain due to supply-demand imbalance and homogenized competition, but the long-term outlook remains positive driven by policy, demand, and technology [10][11][28][30] - Recent regulatory updates, such as the revised vaccine circulation quality supervision measures in Shandong Province, highlight ongoing improvements in vaccine safety mechanisms and regulatory frameworks [6][10] - The approval of innovative vaccines, like the freeze-dried Hib vaccine, reflects the continuous progress of domestic vaccine companies [6][10] Market Performance - The vaccine sector saw a 0.78% increase last week, with a cumulative decline of 4.83% since the beginning of 2025 [7][13] - The relative performance compared to the CSI 300 index shows a decline of 3% over the past month and 30% over the past year [6][9] Valuation Metrics - The vaccine sector's PE (ttm) is 100.69X, with a year-to-date maximum of 111.89X and a minimum of 28.67X, indicating a slight increase from the previous period [9][22] - The PB (lf) stands at 1.85X, with a year-to-date maximum of 2.29X and a minimum of 1.69X, reflecting a stable valuation range [9][22] Investment Recommendations - The report suggests focusing on companies with strong R&D capabilities and differentiated product lines, recommending companies like CanSino and Kanghua Biotech for their innovation and market positioning [10][11][30]

Core Viewpoint - The company, Ai Mei Vaccine, is poised for significant growth with the upcoming commercialization of key vaccine products and a reduction in R&D expenses, leading to a strong financial outlook for 2025 and beyond [1][2] Group 1: Financial Performance - Ai Mei Vaccine reported stable revenue for the first half of 2025, supported by the impending launch of four major vaccine products [1] - The company is expected to achieve profitability by 2026, with sales projected to grow at a compound annual growth rate (CAGR) of 45% from 2025 to 2027 [2] Group 2: Product Development - Four major vaccine products are nearing commercialization: - The registration application for the updated rabies vaccine has been accepted - The 13-valent pneumonia conjugate vaccine has applied for registration and completed on-site verification - The 23-valent pneumonia polysaccharide vaccine has completed Phase III clinical serum testing and is entering the statistical unblinding phase - The updated high-efficiency diploid rabies vaccine is in Phase III clinical trials, with a registration application expected in 2026 [1] - The company has 20 vaccine products in development across 12 disease areas, with 23 clinical approvals and 24 ongoing clinical trials, including 7 innovative Class 1 vaccines [1] Group 3: Market Expansion - Ai Mei Vaccine has successfully entered the African market with its quadrivalent meningococcal polysaccharide vaccine and is registering in Central Asia - The rabies vaccine has made its debut in the Central American market - The hepatitis B vaccine is actively undergoing registration processes in Southeast Asia, while the hepatitis A vaccine is progressing in South Asia [1]